Breitenmoser Flavia, Rixecker Aaron, Naef Rahel, Probst Pascal, Horn Nils, Müller Markus K, Dullenkopf Alexander, Welter JoEllen
Institute for Anesthesia, Cantonal Hospital Thurgau, Frauenfeld, Switzerland.
Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland.
Swiss Med Wkly. 2025 May 15;155:4152. doi: 10.57187/s.4152.
To investigate the extent of persistent opioid use among patients undergoing intermediate-to-major elective surgery at a Swiss cantonal hospital and as a secondary aim to identify factors potentially predictive of persistent opioid use (6 to 12 weeks after surgery).
For this single-centre prospective cohort study, all consecutive patients undergoing elective primary hip arthroplasty, partial or complete prostatectomy, caesarean delivery, spinal surgery, intermediate-to-major visceral surgery or major hand surgery were screened for enrolment from June 2022 to May 2023. We collected basic demographic and medical data, perioperative opioid use (converted to morphine milligram equivalents), postoperative complications, and opioid prescriptions issued by the hospital or other healthcare providers. Telephone interviews about opioid use were conducted with patients 6 weeks after surgery. Only those patients who were still taking opioids at the 6-week interview were contacted 12 weeks after surgery. The primary endpoint was the rate of persistent opioid use 6 or 12 weeks after surgery, and the secondary endpoints were (a) the percentage of patients who received and reported filling prescriptions, and (b) the type and amount of opioids dispensed. With persistent opioid use as the dependent variable, bivariate (predictors: pain or preoperative morphine milligram equivalent) and multivariate logistic regression models were used to assess associations (predictors: age, sex, ASA [American Society of Anesthesiologists] score, preoperative pain).
A total of 855 patients were included in the main analysis. Median age was 62 years (interquartile range [IQR] 45-73), 52% were male and postsurgical complications occurred in 51 patients (6%). Fifty-six patients (7%) were preoperative opioid users. At discharge, 40 patients (5%) received an opioid prescription. Of the 724 patients who completed the 6-week follow-up interview, 30 (4%) had filled an opioid prescription (17 hospital-issued, 9 from an external source and 4 from both). Of the 30 patients (4%) who took opioids, the median length of consumption was 7 days (IQR 3-18). Seventeen patients (2%, 9 preoperative users) were taking opioids after 6 weeks. Seven of these 724 patients (1%, 5 preoperative users) continued use at 12 weeks postoperatively. Bivariate logistic regression analyses showed preoperative pain levels (at rest and during movement) were associated with persistent opioid use (odds ratio [OR] 1.27, 95% confidence interval [CI]: 1.11-1.46, p = 0.001; OR 1.3, 95% CI: 1.12-1.5, p = 0.001, respectively), as were 6-week postoperative pain levels (OR 1.96, 95% CI: 1.61-2.39, p <0.0001; OR 1.82, 95% CI: 1.52-2.18, p <0.0001, respectively). The median preoperative morphine milligram equivalent of persistent opioid users was 60 (IQR 30-180) versus 22.5 (IQR 15-30) in non-persistent users (p = 0.0155). There was a slight positive association between higher preoperative morphine milligram equivalent dosage and persistent postoperative opioid use (OR 1.024, 95% CI: 1.003-1.0456, p = 0.023), with a 2.4% increase in the likelihood of prolonged use per morphine milligram equivalent unit. After controlling for potential confounding factors, multivariate logistic regression analyses indicated associations with higher ASA score (OR 11.8, 95% CI: 2.48-56.51, p = 0.002) and preoperative pain levels (OR 1.23, 95% CI: 1.05-1.43, p = 0.008).
Only a small proportion (1%) of surgical patients continued opioid use 12 weeks after intermediate-to-major elective surgery, with an even much lower proportion (0.3%) having been opioid-naive before surgery. This low rate of prolonged opioid use may be due to the restrictive prescription policy of the centre and local healthcare providers.
调查瑞士一家州立医院接受中大型择期手术患者中持续使用阿片类药物的情况,并作为次要目的,确定可能预测持续使用阿片类药物(术后6至12周)的因素。
在这项单中心前瞻性队列研究中,对2022年6月至2023年5月期间所有连续接受择期初次髋关节置换术、部分或全前列腺切除术、剖宫产、脊柱手术、中大型内脏手术或大型手部手术的患者进行筛选以纳入研究。我们收集了基本人口统计学和医学数据、围手术期阿片类药物使用情况(转换为吗啡毫克当量)、术后并发症以及医院或其他医疗服务提供者开具的阿片类药物处方。术后6周对患者进行关于阿片类药物使用情况的电话访谈。仅对那些在6周访谈时仍在服用阿片类药物的患者在术后12周进行联系。主要终点是术后6周或12周持续使用阿片类药物的比例,次要终点是(a)接受并报告已配药处方的患者百分比,以及(b)所配阿片类药物的类型和数量。以持续使用阿片类药物作为因变量,采用双变量(预测因素:疼痛或术前吗啡毫克当量)和多变量逻辑回归模型来评估相关性(预测因素:年龄、性别、美国麻醉医师协会[ASA]评分、术前疼痛)。
共有855例患者纳入主要分析。中位年龄为62岁(四分位间距[IQR]45 - 73),52%为男性,51例患者(6%)发生术后并发症。56例患者(7%)术前使用阿片类药物。出院时,40例患者(5%)接受了阿片类药物处方。在完成6周随访访谈的724例患者中,30例(4%)已配阿片类药物处方(17例由医院开具,9例来自外部来源,4例两者都有)。在30例(4%)服用阿片类药物的患者中,中位用药时长为7天(IQR 3 - 18)。17例患者(2%,9例术前使用者)在6周后仍在服用阿片类药物。在这724例患者中,7例(1%,5例术前使用者)在术后12周仍继续使用。双变量逻辑回归分析显示,术前疼痛水平(静息时和活动时)与持续使用阿片类药物相关(优势比[OR]1.27,95%置信区间[CI]:1.11 - 1.46,p = 0.001;OR 1.3,95% CI:1.12 - 1.5,p = 0.001),术后6周疼痛水平也与之相关(OR 1.96,95% CI:1.61 - 2.39,p <0.0001;OR 1.82,95% CI:1.52 - 2.18,p <0.0001)。持续使用阿片类药物患者的术前吗啡毫克当量中位数为60(IQR 30 - 180),而非持续使用者为22.5(IQR 15 - 30)(p = 0.0155)。术前较高的吗啡毫克当量剂量与术后持续使用阿片类药物之间存在轻微正相关(OR 1.024,95% CI:1.003 - 1.0456,p = 0.023),每增加一个吗啡毫克当量单位,延长使用的可能性增加2.4%。在控制潜在混杂因素后,多变量逻辑回归分析表明与较高的ASA评分(OR 11.8,95% CI:2.48 - 56.51,p = 0.002)和术前疼痛水平(OR 1.23,95% CI:1.05 - 1.43,p = 0.008)相关。
在接受中大型择期手术后12周,仅有一小部分(1%)手术患者继续使用阿片类药物,术前未使用过阿片类药物的患者比例甚至更低(0.3%)。这种低比例的长期阿片类药物使用可能归因于该中心和当地医疗服务提供者的限制性处方政策。